Soligenix Inc (SNGX)
NASDAQ:SNGX
Want to see SNGX full AI Analyst Report?
Top Page
Soligenix
(NASDAQ:SNGX)
Select Model
Select Model
Rating:46Neutral
Price Target:
$1.00
▼(-30.56% Downside)
Action:ReiteratedDate:04/01/26
The score is held down primarily by weak financial performance: minimal revenue, widening losses, and sustained cash burn that imply continued reliance on financing. Technicals are neutral-to-slightly bearish with the stock below key moving averages. Corporate updates provide a modest positive catalyst (Phase 3 progress and near-term milestones), but dilution risk from financing tools and the lack of profitable operations keep the overall score below average.
Positive Factors
Orphan and regulatory designations for SGX945
EMA/EC orphan designation and related UK/US designations create durable regulatory incentives (10-year EU exclusivity, protocol assistance, centralized review access). These structural protections raise commercial optionality and partnership appeal for a small biotech pursuing rare-disease approvals.
Negative Factors
Effectively zero product revenue
As a pre‑commercial biotech, Soligenix lacks recurring product revenue, leaving operations fully reliant on grants, collaborations and financing. Persistent absence of sales limits ability to self-fund R&D, prolongs dependence on capital markets, and increases execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Orphan and regulatory designations for SGX945
EMA/EC orphan designation and related UK/US designations create durable regulatory incentives (10-year EU exclusivity, protocol assistance, centralized review access). These structural protections raise commercial optionality and partnership appeal for a small biotech pursuing rare-disease approvals.
Read all positive factors
Soligenix (SNGX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.85M
Dividend YieldN/A
Average Volume (3M)272.26K
Price to Earnings (P/E)―
Beta (1Y)0.12
Revenue GrowthN/A
EPS Growth53.13%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.32
Shares Outstanding10,306,079
10 Day Avg. Volume140,297
30 Day Avg. Volume272,259
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.31
Price to Sales (P/S)0.00
P/FCF Ratio-0.68
Enterprise Value/Market Cap0.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.37K
Enterprise Value/Ebitda-0.37
Forecast
1Y Price Target
$10.00Price Target Upside594.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.85
Revenue Forecast (FY)N/A
Soligenix Business Overview & Revenue Model
Company Description
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Spec...
How the Company Makes Money
Soligenix generates revenue primarily through (1) government and nongovernment research and development funding and (2) collaborations and related payments tied to its development programs. A material component of its historical revenue has come f...
Soligenix Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
42
Neutral
Cash Flow
12
Very Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 250.00K | 33.35K |
| Gross Profit | 0.00 | -119.37K | -742.05K | -300.82K | -695.29K |
| EBITDA | -11.85M | -9.46M | -7.67M | -14.11M | -12.48M |
| Net Income | -11.08M | -8.27M | -6.14M | -13.80M | -12.55M |
Balance Sheet | |||||
| Total Assets | 9.24M | 8.97M | 9.80M | 14.28M | 26.87M |
| Cash, Cash Equivalents and Short-Term Investments | 7.94M | 7.82M | 8.45M | 13.36M | 26.04M |
| Total Debt | 358.14K | 1.48M | 3.49M | 10.24M | 9.96M |
| Total Liabilities | 3.94M | 4.85M | 7.27M | 16.75M | 16.15M |
| Stockholders Equity | 5.29M | 4.12M | 2.52M | -2.47M | 10.72M |
Cash Flow | |||||
| Free Cash Flow | -10.27M | -8.40M | -8.60M | -12.66M | -11.75M |
| Operating Cash Flow | -10.27M | -8.40M | -8.60M | -12.65M | -11.74M |
| Investing Cash Flow | -5.88K | 0.00 | 0.00 | -13.07K | -11.79K |
| Financing Cash Flow | 10.39M | 7.76M | 3.66M | 76.82K | 19.06M |
Soligenix Technical Analysis
Neutral
1.44
Price Trends
1.16
Positive
1.29
Negative
1.65
Negative
Market Momentum
-0.01
Negative
50.80
Neutral
66.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNGX, the sentiment is Neutral. The current price of 1.44 is above the 20-day moving average (MA) of 1.16, above the 50-day MA of 1.16, and below the 200-day MA of 1.65, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 50.80 is Neutral, neither overbought nor oversold. The STOCH value of 66.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SNGX.
Soligenix Risk Analysis
Soligenix disclosed 47 risk factors in its most recent earnings report. Soligenix reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Soligenix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $11.32M | -9.61 | -22.03% | ― | -41.76% | 87.36% | |
46 Neutral | $11.85M | -0.60 | -248.01% | ― | ― | 53.13% | |
45 Neutral | $2.85M | ― | -489.66% | ― | 8.52% | 79.51% | |
45 Neutral | $11.70M | -0.47 | -119.35% | ― | 178.19% | 68.57% | |
41 Neutral | $6.75M | -0.33 | ― | ― | ― | ― |
* Healthcare Sector Average
SNGX
Soligenix
1.17
-0.93
-44.29%
BLRX
Bioline RX Ltd Sponsored ADR
2.39
-0.49
-17.01%
CANF
Can-Fite BioPharma
3.08
-20.92
-87.17%
GOVX
GeoVax Labs
1.23
-19.51
-94.07%
AIMD
Ainos
1.66
-1.09
-39.64%
Soligenix Corporate Events
Business Operations and StrategyProduct-Related Announcements
Soligenix Provides Shareholder Update on Rare Disease Pipeline
Positive
Feb 12, 2026
On February 12, 2026, Soligenix issued a shareholder update outlining clinical and corporate progress across its rare disease pipeline, including the actively enrolling confirmatory Phase 3 FLASH2 trial of HyBryte in early-stage cutaneous T‑...
Business Operations and StrategyPrivate Placements and Financing
Soligenix Establishes At-The-Market Equity Offering Program
Positive
Jan 23, 2026
On January 23, 2026, Soligenix, Inc. entered into an at-the-market issuance sales agreement with Rodman Renshaw, LLC, allowing the company, at its discretion, to sell up to $3.45 million of its common stock through Rodman as sales agent under an ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.